Objective: To provide a comprehensive understanding of APOE ε4 effects across the lifespan on the 3 main neuroimaging biomarkers.
Methods: Two hundred seven community-dwelling, cognitively normal APOE ε4 carriers and noncarriers aged 20-87 years were involved in this study. They underwent structural MRI, fluorodeoxyglucose-PET, and florbetapir-PET scans. The effects of APOE, age, and APOE × age interaction were assessed voxel-wise for each modality.
Results: There was no significant effect of APOE or APOE × age interaction on gray matter volume and glucose metabolism, although decreases with age tended to be stronger in noncarriers than in carriers. In contrast, β-amyloid (Aβ) deposition was significantly higher in carriers compared with noncarriers in a largely distributed network, and there was a significant APOE × age interaction such that Aβ deposition increased nonlinearly with age in APOE ε4 carriers only.
Conclusions: Our findings highlight a differential effect of APOE ε4 on amyloid vs neurodegeneration biomarkers. APOE ε4 mainly influences Aβ deposition, while the effects on gray matter volume and glucose metabolism are at best subtle.
Clinicaltrialsgov identifier: NCT01638949.
© 2016 American Academy of Neurology.